Mutational analysis of plasminogen activator inhibitor-1. Interactions of α-helix F and its neighbouring structural elements regulates the activity and the rate of latency transition

European Journal of Biochemistry

Volumn 270, Issue 8, 2003, Pages 1680-1688

  Wind, Troels ^a,b   Jensen, Jan K ^a   Dupont, Daniel M ^a   Kulig, Paulina ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alignment; Conformation; Mutational analysis; PAI 1; Proteases; Serpin

Indexed keywords

ALANINE; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BETA SHEET; COMPLEX FORMATION; CONTROLLED STUDY; LATENT PERIOD; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI; HALF-LIFE; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

INSERTION SEQUENCES;

EID: 0038071492     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2003.03524.x     Document Type: Article

References (43)

1. Huntington, J.A., Read, R.J. & Carrell, R.W. (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923-926.
2. Irving, J.A., Pike, R.N., Lesk, A.M. & Whisstock, J.C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845-1864.
3. Gils, A. & Declerck, P.J. (1998) Structure-function relationships in serpins: current concepts and controversies. Thromb. Haemost. 80, 531-541.
4. Ye, S. & Goldsmith, E.J. (2001) Serpins and other covalent protease inhibitors. Curr. Opin. Struct. Biol. 11, 740-745.
5. Wind, T., Hansen, M., Jensen, J.K. & Andreasen, P.A. (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1. Roles of the reactive centre loop, the shutter region, the flexible joint-region and the small serpin fragment. Biol. Chem. 383, 21-36.
6. Mottonen, J., Strand, A., Symersky, J., Sweet, R.M., Danley, D.E., Geoghegan, K.F., Gerard, R.D. & Goldsmith, E.J. (1992) Structural basis of latency in plasminogen activator inhibitor-1. Nature 355, 270-273.
7. Carrell, R.W., Stein, P.E., Fermi, G. & Wardell, M.R. (1994) Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2, 257-270.
8. 1-antitrypsin. J. Biol. Chem. 270, 5282-5288.
9. 1-antichymotrypsin in chronic bronchitis and emphysema. J. Biol. Chem. 273, 3695-3701.
10. Lawrence, D.A., Olson, S.T., Palaniappan, S. & Ginsburg, D. (1994) Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 33, 3643-3648.
11. Tucker, H.M., Mottonen, J., Goldsmith, E.J. & Gerard, R.D. (1995) Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat. Struct. Biol. 2, 442-445.
12. Sui, G.C. & Wiman, B. (1998) Stability of plasminogen activator inhibitor-1: role of tyrosine221. FEBS Lett. 423, 319-323.
13. Sui, G.C. & Wiman, B. (2000) The B β-sheet in the PAI-1 molecule plays an important role for its stability. Thromb. Haemost. 83, 896-901.
14. Mångs, H., Sui, G.C. & Wiman, B. (2000) PAI-1 stability: the role of histidine residues. FEBS Lett. 475, 192-196.
15. Ngo, T.H., Hoylaerts, M.F., Knockaert, I., Brouwers, E. & Declerck, P.J. (2001) Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties. J. Biol. Chem. 276, 26243-26248.
16. Berkenpas, M.B., Lawrence, D.A. & Ginsburg, D. (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977.
17. Sharp, A.M., Stein, P.E., Pannu, N.S., Carrell, R.W., Berkenpas, M.B., Ginsburg, D., Lawrence, D.A. & Read, R.J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Struct. Fold. Des. 7, 111-118.
18. Stout, T.J., Graham, H., Buckley, D.I. & Matthews, D.J. (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39, 8460-8469.
19. Nar, H., Bauer, M., Stassen, J.M., Lang, D., Gils, A. & Declerck, P.J. (2000) Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297, 683-695.
20. Stoop, A.A., Eldering, E., Dafforn, T.R., Read, R.J. & Pannekoek, H. (2001) Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J. Mol. Biol. 305, 773-783.
21. Komissarov, A.A., Declerck, P.J. & Shore, J.D. (2002) Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J. Biol. Chem. 277, 43858-43865.
22. Bijnens, A.P., Gils, A., Knockaert, I., Stassen, J.M. & Declerck, P.J. (2000) Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275, 6375-6380.
23. Schousboe, S.L., Egelund, R., Kirkegaard, T., Preissner, K.T., Rodenburg, K.W. & Andreasen, P.A. (2000) Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F. Thromb. Haemost. 83, 742-751.
24. Wind, T., Jensen, M.A. & Andreasen, P.A. (2001) Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur. J. Biochem. 268, 1095-1106.
25. Vleugels, N., Gils, A., Bijnens, A.P., Knockaert, I. & Declerck, P.J. (2000) The importance of helix F in plasminogen activator inhibitor-1. Biochim. Biophys. Acta. 1476, 20-26.
26. Gettins, P.G. (2002) The F-helix of serpins plays an essential, active role in the proteinase inhibition mechanism. FEBS Lett. 523, 2-6.
27. Carrell, R.W. & Stein, P.E. (1996) The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol. Chem. Hoppe Seyler 377, 1-17.
28. Christensen, J.H., Hansen, P.K., Lillelund, O. & Thøgersen, H.C. (1991) Sequence-specific binding of the N-terminal three-finger fragment of Xenopus transcription factor IIIA to the internal control region of a 5S RNA gene. FEBS Lett. 281, 181-184.
29. Andreasen, P.A., Riccio, A., Welinder, K.G., Douglas, R., Sartorio, R., Nielsen, L.S., Oppenheimer, C., Blasi, F. & Danø, K. (1986) Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 209, 213-218.
30. Gill, S.C. & von Hippel, P.H. (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319-326.
31. Jensen, J.K., Wind, T. & Andreasen, P.A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett. 521, 91-94.
32. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N. & Bourne, P.E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235-242.
33. 1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9, 1274-1281.
34. 1-antitrypsin, structure and implications for function and metabolism. Protein Eng. 2, 407-415.
35. Skinner, R., Abrahams, J.P., Whisstock, J.C., Lesk, A.M., Carrell, R.W. & Wardell, M.R. (1997) The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site. J. Mol. Biol. 266, 601-609.
36. 1-antitrypsin. J. Mol. Biol. 296, 685-699.
37. Hansen, M., Busse, M.N. & Andreasen, P.A. (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur. J. Biochem. 268, 6274-6283.
38. Jensen, S., Kirkegaard, T., Pedersen, K.E., Busse, M., Preissner, K.T., Rodenburg, K.W. & Andreasen, P.A. (2002) The role of β-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin. Biochim. Biophys. Acta. 1597, 301-310.
39. Stoop, A.A., Jespers, L., Lasters, I., Eldering, E. & Pannekoek, H. (2000) High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). J. Mol. Biol. 301, 1135-1147.
40. 1-antitrypsin. J. Biol. Chem. 274, 11072-11077.
41. Im, H. & Yu, M.H. (2000) Role of Lys335 in the metastability and function of inhibitory serpins. Protein Sci. 9, 934-941.
42. Lawrence, D.A., Olson, S.T., Muhammad, S., Day, D.E., Kvassman, J.O., Ginsburg, D. & Shore, J.D. (2000) Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into β-sheet A. J. Biol. Chem. 275, 5839-5844.
43. Cabrita, L.D., Whisstock, J.C. & Bottomley, S.P. (2002) Probing the role of the F-helix in serpin stability through a single tryptophan substitution. Biochemistry. 41, 4575-4581.